PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for PMCB. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: PMCB is a Sell candidate.
PMCB stock price ended at $0.76 on 月曜日, after rising 5.56%
On the latest trading day Apr 27, 2026, the stock price of PMCB rose by 5.56%, climbing from $0.71 to $0.76. During the session, the stock saw a volatility of 11.43%, with prices oscillating between a daily low of $0.70 and a high of $0.78. Notably, trading volume dropped by 64.2K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 131.8K shares were traded, equating to a market value of approximately $8.1M.